Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
Thrombosis and Haemostasis · 01.05.2025 · 125 (05) · 449-459
DOI: 10.1055/a-2384-3585 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.05.2025. Verfasst von Midori Shima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Immunosuppressive Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical.
Abstract (Originalsprache)
Primary analysis of the phase III AGEHA study suggested a favorable benefit–risk profile for emicizumab prophylaxis in patients with acquired hemophilia A (PwAHA); however, only patients undergoing immunosuppressive therapy (IST; Cohort 1) were included. To present final analysis results of AGEHA, including data on IST-ineligible patients (Cohort 2) and on long-term prophylaxis with emicizumab. For patients in both Cohorts 1 and 2, emicizumab was administered subcutaneously at 6 mg/kg on Day 1, 3 mg/kg on Day 2, and 1.5 mg/kg once weekly from Day 8 onward. Twelve patients (Cohort 1) and two patients (Cohort 2) were enrolled. Duration of emicizumab treatment was 8 to 639 days (median: 44.5 days) in Cohort 1 and 64 and 450 days in Cohort 2. In both cohorts, no major bleeds were observed after initial emicizumab administration. Six patients started their first rehabilitation sessions during emicizumab treatment and no rehabilitation-related bleeds occurred. Twenty-three surgeries were performed under emicizumab prophylaxis and there were no bleeds related to surgeries. Although asymptomatic deep vein thrombosis was reported in one patient in the primary analysis, no other thrombotic events occurred thereafter. Two patients developed anti-emicizumab antibodies, one of whom showed accelerated emicizumab clearance. Tailored IST approaches (delayed initiation, no use, or reduced dose) were successfully executed in three patients undergoing emicizumab prophylaxis. These results suggest that emicizumab prophylaxis has a favorable benefit–risk profile in PwAHA regardless of eligibility for IST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan.
- Department of Pediatrics, Nara Medical University, Kashihara, Japan.
- Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
- Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
ORCID-Profile: Ryota Kobayashi, Ryoto Ozaki, Koichiro Yoneyama
Förderung
- Chugai Pharmaceutical
Zitieren
APA
Shima, M., Suzuki, N., Nishikii, H., Amano, K., Ogawa, Y., Kobayashi, R., Ozaki, R., Yoneyama, K., Mizuno, N., Sakaida, E., Saito, M., Okamura, T., Ito, T., Hattori, N., Higasa, S., Seki, Y., & Nogami, K. (2025). Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thrombosis and Haemostasis, 125(05), 449-459. https://doi.org/10.1055/a-2384-3585
Vancouver
Shima M, Suzuki N, Nishikii H, Amano K, Ogawa Y, Kobayashi R, et al. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thrombosis and Haemostasis. 2025;125(05):449-459. doi:10.1055/a-2384-3585
BibTeX
@article{Shima2025,
author = {Shima, Midori and Suzuki, Nobuaki and Nishikii, Hidekazu and Amano, Kagehiro and Ogawa, Yoshiyuki and Kobayashi, Ryota and Ozaki, Ryoto and Yoneyama, Koichiro and Mizuno, Narumi and Sakaida, Emiko and Saito, Makoto and Okamura, Takashi and Ito, Toshihiro and Hattori, Norimichi and Higasa, Satoshi and Seki, Yoshinobu and Nogami, Keiji},
title = {Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {05},
pages = {449--459},
doi = {10.1055/a-2384-3585}
}
EUVIMED